Filing Details

Accession Number:
0001140361-17-008884
Form Type:
4
Zero Holdings:
No
Publication Time:
2017-02-23 18:12:30
Reporting Period:
2017-02-22
Filing Date:
2017-02-23
Accepted Time:
2017-02-23 18:12:30
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
874716 Idexx Laboratories Inc IDXX In Vitro & In Vivo Diagnostic Substances (2835) 010393723
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1184149 W Jonathan Ayers One Idexx Drive
Westbrook ME 04092
Chairman, President & Ceo Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2017-02-22 2,286 $43.71 995,947 No 4 M Direct
Common Stock Acquisiton 2017-02-22 50,000 $38.80 1,045,947 No 4 M Direct
Common Stock Disposition 2017-02-22 31,795 $142.55 1,014,152 No 4 S Direct
Common Stock Disposition 2017-02-22 3,205 $142.84 1,010,947 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Incentive Stock Option (right-to-buy) Disposition 2017-02-22 2,286 $0.00 2,286 $43.71
Common Stock Non-Qualified Stock Option (right-to-buy) Disposition 2017-02-22 50,000 $0.00 50,000 $38.80
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2019-02-13 No 4 M Direct
40,000 2018-02-13 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 98,000 Indirect by Ayers Family Trust
Footnotes
  1. Represents the weighted average sales price of the shares sold ranging from a low of $141.80 to a high of $142.795 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
  2. Represents the weighted average sales price of the shares sold ranging from a low of $142.80 to a high of $143.00 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
  3. Grant of option to buy 1,143 shares of IDEXX Laboratories, Inc. common stock that became exercisable on February 14, 2017, without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.
  4. Grant of option to buy 58,712 shares of IDEXX Laboratories, Inc. common stock that became exercisable in four annual installments of 12,000 shares each beginning on February 14, 2012 and as to the remaining 10,712 shares on February 14, 2016, The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.
  5. Not applicable.